Microdermics Closes $1 Million Seed Round - Apr 20, 2017

Microneedle Wafer File_003.jpeg
Microdermics' revolutionary drug delivery system is commercially scalable, customizable, less painful, and addresses widespread “needle phobia”

Microdermics today announced completion of its $1 million financing round, which was oversubscribed and received robust global interest. Microdermics has developed the only commercially scalable, low-cost, customizable, metal, hollow, microneedle platform that provides efficient delivery of vaccines and biologics—addressing the reliance worldwide on the 160-year old, generic hypodermic needle.

Read more here.